Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?

Katerina Markopoulou, Joanna M. Biernacka, Sebastian M. Armasu, Kari J. Anderson, J. Eric Ahlskog, Bruce A. Chase, Sun Ju Chung, Julie M. Cunningham, Matthew Farrer, Roberta Frigerio, Demetrius M. Maraganore

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

α-Synuclein gene (SNCA) multiplications cause familial parkinsonism and allele-length polymorphisms within the SNCA dinucleotide repeat REP1 increase the risk for developing Parkinson's disease (PD). Since SNCA multiplications increase SNCA expression, and REP1 genotypes that increase the risk of developing PD show increased SNCA expression in cell-culture systems, animal models, and human blood and brain, PD therapies seek to reduce SNCA expression. We conducted an observational study of 1098 PD cases to test the hypothesis that REP1 genotypes correlated with reduced SNCA expression are associated with better motor and cognitive outcomes. We evaluated the association of REP1 genotypes with survival free of Hoehn and Yahr stages 4 or 5 (motor outcome) and of Modified Telephone Interview for Cognitive Status score ≤27 or Alzheimer's Disease Dementia Screening Interview score ≥2 (cognitive outcome). Median disease duration at baseline was 3.3 years and median lag time from baseline to follow-up was 7.8 years. Paradoxically, REP1 genotypes associated with increased risk of developing PD and increased SNCA expression were associated with better motor (HR = 0.87, p = 0.046, covariate-adjusted age-scale analysis; HR = 0.85, p = 0.020, covariate-adjusted time-scale analysis) and cognitive outcomes (HR = 0.90, p = 0.12, covariate-adjusted age-scale analysis; HR = 0.85, p = 0.023, covariate-adjusted time-scale analysis). Our findings raise the possibility that SNCA has a dual, opposing, and time-dependent role. This may have implications for the development of therapies that target SNCA expression.

Original languageEnglish (US)
Pages (from-to)584-589
Number of pages6
JournalParkinsonism and Related Disorders
Volume20
Issue number6
DOIs
StatePublished - Jun 2014

Keywords

  • AD-8
  • Bp
  • H&Y
  • HR
  • LD
  • MEPD
  • MMSE
  • Outcomes
  • PD
  • Parkinson's disease
  • SNCA
  • SNP
  • TICS-M
  • UPDRS
  • α-Synuclein gene

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?'. Together they form a unique fingerprint.

  • Cite this

    Markopoulou, K., Biernacka, J. M., Armasu, S. M., Anderson, K. J., Ahlskog, J. E., Chase, B. A., Chung, S. J., Cunningham, J. M., Farrer, M., Frigerio, R., & Maraganore, D. M. (2014). Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? Parkinsonism and Related Disorders, 20(6), 584-589. https://doi.org/10.1016/j.parkreldis.2014.02.021